From 3rd to 5th July, the 15th China Dairy Industry Conference, the 2024 China Dairy D20 Summit and the China Dairy Industry Exhibition were held in Wuhan, Hubei Province. During the event, the China Dairy Association formally announced the list of “Major Scientific and Technological Innovation Achievements in the Dairy Industry”. Synaura Biotech was honoured with the “2024 Major Scientific and Technological Innovation Achievement Award in Dairy” for its project “Breakthrough Production Technology and Application of Human Milk Oligosaccharides (HMOs)”, once again receiving high recognition from the industry. The ‘Major Scientific and Technological Innovation Achievement Award in Dairy Industry’ aims to fully explore and showcase outstanding achievements in dairy industry innovation, foster a favourable innovation ecosystem, promote the application and dissemination of scientific and technological innovations, advance technological progress and industrial upgrading within the sector, and enhance the overall competitiveness of the dairy industry. Certificate for the 2024 Major Scientific and Technological Innovation Achievement Award in the Dairy Industry As China's leading domestic HMO producer, Synaura Biotech employs advanced synthetic biology techniques to achieve efficient and safe HMO production through microbial fermentation. The bacterial strains undergo rigorous screening and safety assessments, meeting National Health Commission standards and establishing a robust foundation for exceptional product quality. Synaura Biotech is wholly committed to advancing compliant domestic production. With an ingenious spirit, it continuously refines production processes and perfects products, striving to deliver HMOs characterised by uniform particle size, high purity, purity without odour, and exceptional value for money. Authoritative third-party testing has confirmed that Synaura HMO possesses the same structural composition as breast milk HMO*. Extensive customer validation has demonstrated that Synaura's HMOs have gained widespread market recognition for their exceptional quality, ease of application, and adaptability to diverse production methods including dry and wet processes. This accolade not only acknowledges Synaura's relentless exploration and innovation within the HMO field but also serves as compelling evidence of its immense potential in driving technological advancement and spearheading industrial upgrading within the sector. Looking ahead, Synaura Biotech remains steadfast in its commitment to deepening expertise within the HMO domain. Through continuous exploration of novel technologies and methodologies, the company will deliver increasingly superior products and services. This endeavour aims to bolster the high-quality development of China's dairy industry and contribute sustainably to the nation's health objectives. *The verification results are derived from authoritative third-party scientific data.

Recently, the Foodaily FBIC 2024 Innovation Conference commenced as scheduled at the National Exhibition and Convention Centre (Shanghai). Centred on the theme ‘Breaking Through the Industrial Chain, Co-Creating New Horizons’, the event featured multiple segments including plenary summits, category & thematic forums, and global innovation tastings. Concurrently, the ‘Foodaily 2024 Daily Food Innovation Expo’ and the ‘iSEE Innovation Gala & iSEE Golden Awards Ceremony’ were held. As China's leading HMO innovator, Synaura Biotech was invited to present at the conference's thematic forum and attended the ‘iSEE Innovation Gala and iSEE Golden Awards Ceremony’ as recipient of the ‘Global Food Innovation Technology Award’. Synaura Biotech Honoured with iSEE Global Food Innovation Technology Award As an authoritative award with global influence in the food and beverage industry, the iSEE Global Awards have consistently dedicated themselves to discovering and recognising pioneering innovative enterprises and culinary products worldwide since their inception. To date, they have attracted over 10,000 case submissions. This year's iSEE Global Awards expanded its reach to encompass China, Japan, South Korea, Europe and other regions, gathering a diverse array of innovative participants including international giants, leading local enterprises, traditional brands undergoing transformation, and pioneering newcomers. Figure 1: iSEE Awards Ceremony On 9 May, the iSEE Innovation Gala and iSEE Golden Awards Ceremony concluded successfully, with over 1,000 industry leaders and top media outlets witnessing the unveiling of the 2024 iSEE Global Awards. According to organisers' statistics, this year's global awards attracted over 3,000 brand entries and 4,000 case submissions. Following online preliminary selection and offline initial and final reviews by the organising committee's expert panel, only 50 food innovation technology entries advanced to the final judging stage. As a pioneer in China's HMO sector, Synaura Biotech distinguished itself among over 4,000 domestic and international entries. Its proposal, ‘Microbial Fermentation Method for Preparing 2'-Fucosyllactose (2'-FL) and Its Industrial Applications,’ was honoured with the 2024 iSEE Global Food Innovation Technology Award. This achievement not only demonstrates Synaura Biotech's exceptional innovation capabilities within the HMO sector but also showcases the outstanding innovative accomplishments of domestic Chinese enterprises to the entire industry and consumers. Figure 2: Synaura Award Certificate Additionally, Synaura Biotech was invited to participate in the ‘iSEE Global Awards Technology Innovation Gallery’, showcasing its position as an exemplary innovative technology enterprise at the conference venue. Throughout the exhibition period, the stand attracted a steady stream of visitors, with numerous attendees and industry experts demonstrating keen interest in Synaura's innovative technologies and product solutions, pausing frequently to seek further information. Zhang Xiaowei, Head of Business Development at Synaura, represented the company during a live interview broadcast from the ‘iSEE Technology Gallery’, sharing insights with online audiences on Synaura Biotech's technological advantages as China's leading HMO innovator within the synthetic biology sector. Figures 3 and 4: Synaura Exhibition Stand Layout Keynote Address at the Forum On the afternoon of 10 May, Ms Yao Fei, Head of Applied R&D at Synaura Biotech, represented the company as an invited speaker at the ‘Dairy Innovation’ category forum. She delivered a presentation entitled ‘Synthetic Biology: The New Productivity in Food Production Starts with HMOs’. Ms Yao Fei addressed the audience by focusing on novel food production capabilities, highlighting the significant role of artificial intelligence and synthetic biology in driving innovation within the food sector. Using HMOs as a prime example, she provided a detailed overview of global research achievements and current applications, while offering a comprehensive outlook on future development prospects. Figure 5: Scene from the presentation This invitation and accolade not only underscore the high regard held by both industry insiders and outsiders for Synaura Biotech's scientific research capabilities and innovative achievements, but also serve as compelling evidence of the company's robust technical prowess in the independent development of HMO products. It demonstrates the exceptional capabilities of a Chinese domestic enterprise within the HMO field. Synaura's 2'-FL is produced using advanced microbial fermentation technology, renowned for its uniform particle size, high purity (≥96%), and absence of residual acetic acid odour. Authoritative third-party testing has confirmed that Synaura's HMO products possess identical structural composition to breast milk HMOs*. Figure 6: Five Key Advantages of Synaura™ HMO Through extensive application validation by numerous clients, Synaura Biotech's HMO has gained widespread market recognition for its exceptional quality, user-friendly application, and high adaptability to diverse production processes including dry and wet methods. Moving forward, Synaura Biotech remains steadfast in its founding mission, continuously driving technological innovation within the food sector to provide healthier, safer choices for millions of households. *The verification results are derived from authoritative third-party scientific data.

Recently, Synaura Biotech (Shanghai) Co., Ltd. (‘Synaura Biotech’) has successfully secured nearly 100 million yuan in Pre-A round financing. This funding round was led by CICC Qide Fund, under the renowned investment institution CICC Capital, with participation from Moutai Fund. The capital raised will be allocated towards new product development, laboratory construction, industrialisation implementation, and commercialisation advancement, injecting fresh momentumSynaura Biotech's innovative development within the HMO sector. Established in February 2022, Synaura Biotech stands as China's pioneering domestic HMO innovator, spearheading future nutritional trends with its proprietary HMO products. Its HMO offerings set new benchmarks in health nutrition through exceptional properties including high purity, low impurity levels, and odourlessness. Leveraging cutting-edge R&D capabilities and precision fermentation techniques, Synaura Biotech delivers solutions that meet both client innovation requirements and consumer demands for premium nutritional quality. Dr Huang Xu, Managing Director of CICC Capital, remarked that HMOs have been a key focus for numerous dairy enterprises in recent years. Following formal approval in October 2023, they will spearhead a new wave of advancement within the infant formula and dairy sectors. As China's first approved enterprise, Synaura Biotech is poised to seize opportunities in the global nutritional supplements market and soar to new heights, bolstered by shareholder resources and driven by its dedicated management team. Maotai Fund serves as the market-oriented equity investment platform under China Kweichow Moutai (Group) Co., Ltd. (‘Maotai Group’). Focusing on cutting-edge developments and applications in biotechnology, Maotai Fund has recognised Synaura Biotech's growth potential within the synthetic biology sector. Existing shareholder Beihai Mengniu Venture Capital has made a follow-on investment in this round. As a wholly-owned incubator platform under Mengniu Group and a key component of its strategic investment arm, Beihai Mengniu Venture Capital participated in Synaura Biotech's founding through investment and incubation. This additional investment underscores Mengniu's confidence and commitment to its strategic positioning in the synthetic biology sector. Moving forward, with the combined strengths of all shareholders, Synaura Biotech will accelerate the development of its R&D innovation capabilities. The company will prioritise the development of HMOs and new pipelines, further enhance its local HMO expertise and influence, continuously cultivate new productive forces, and contribute to the high-quality development of the dairy industry. About CICC Capital CICC Capital serves as the private equity fund management platform of China International Capital Corporation Limited (‘CICC’), overseeing the firm's domestic and international private investment fund operations. It has evolvedone of China's leading private investment management institutions. Currently, the funds under its management encompass RMB corporate equity funds, fund-of-funds, real estate funds, infrastructure funds, and USD corporate equity funds.